Next Day Disclosure Return
Filed with HKEX · Stock code 1672 · · 8 pages · English
Earlier from Ascletis Pharma
- Grant of share options
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
- Voluntary announcement - ascletis to present study results of oral small molecule GIPR agonist ASC48 and GLP-1R/GIPR/GCGR triple peptide agonist ASC37 at ObesityWeek 2026
- Voluntary announcement - ascletis' oral small molecule GLP-1, ASC30, demonstrated placebo-adjusted HBA1C reduction of 1.7% at 12 weeks from its U.S. phase II study in participants with diabetes
- Voluntary announcement - ascletis announces FDA IND submission of ASC39, an oral small molecule selective amylin receptor agonist for the treatment of obesity
Follow Ascletis Pharma into a list and get an email when it puts out news.
Follow Ascletis Pharma